Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.52 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059203 | 1.00 | TLR7 (0.52) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL14870976 | 0.82 | TLR7 (0.56) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL2058834 | 0.81 | ALDH1A1 (0.39) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL2058833 | 0.81 | ALDH1A1 (0.39) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL28761870 | 0.79 | TLR7 (0.58) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL842364 | 0.79 | TLR7 (0.62) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL2059416 | 0.78 | TLR7 (0.32) | TLR7ADORA2A | |
| SCHEMBL2059415 | 0.78 | TLR7 (0.32) | TLR7ADORA2A | |
| SCHEMBL8572870 | 0.78 | TLR7 (0.74) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL6723566 | 0.77 | TLR7 (0.65) | TLR7TLR8NUDT1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968563-B2 | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100069427-A9 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090062328-A1 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1846405-A2 | OXIME AND HYDROXYLAMINE SUBSTITUTED IMIDAZO 4,5-C RING COMPOUNDS AND METHODS | 3M Innovative Properties Company (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006086634-A2 | OXIME AND HYDROXYLAMINE SUBSTITUTED IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069427-A9 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | IFNG, IL4, IRF3 | TLR7 76/4885TLR8 110/4885NUDT1 269/4885 |
| US-20090062328-A1 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | IFNG, IL4, IRF3 | TLR7 76/4885TLR8 110/4885NUDT1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.